Literature DB >> 7110115

Morphine allosterically modulates the binding of [3H]leucine enkephalin to a particulate fraction of rat brain.

R B Rothman, T C Westfall.   

Abstract

Equilibrium binding studies have demonstrated that [3H]leucine enkephalin labels a single class of binding sites in a particulate fraction of rat brain with a dissociation constant (KD) of 3.2 +/- 0.1 nM. Methionine enkephalin was a competitive inhibitor of [3H]leucine enkephalin binding, changing the KD to 14.1 +/- 1.5 nM. In contrast, Scatchard analysis of the binding of [3H]leucine enkephalin in the absence and presence of 10, 50, and 100 nM morphine demonstrated that these concentrations of morphine decreased the number of binding sites by 23%, 32%, and 42%, respectively, with no change in the KD. In contrast, morphine at 500 nM caused a 45% decrease in the number of binding sites and an increase in the KD. On the basis of these data, the inhibitory dissociation constant (KI) of morphine was calculated to 400 +/- 17 nM. The noncompetitive inhibition by morphine of [3H]leucine enkephalin binding was shown to be rapidly reversible, ruling out pseudoirreversible binding of morphine to the enkephalin binding site as the underlying mechanism. Computer analysis of the displacement [3H]leucine enkephalin binding by various concentrations of morphine has demonstrated that an allosteric model, not a two-site model, best describes the observed data. We conclude that at low concentration morphine binds to a receptor not labeled by [3H]leucine enkephalin and by doing so allosterically induces an apparent loss of enkephalin receptors.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7110115

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  14 in total

Review 1.  Development of delta opioid peptides as nonaddicting analgesics.

Authors:  R S Rapaka; F Porreca
Journal:  Pharm Res       Date:  1991-01       Impact factor: 4.200

Review 2.  Mu opioids and their receptors: evolution of a concept.

Authors:  Gavril W Pasternak; Ying-Xian Pan
Journal:  Pharmacol Rev       Date:  2013-09-27       Impact factor: 25.468

3.  Experimental design and estimation of parameters in complex radioligand binding systems.

Authors:  C M Staschen; L D Homer
Journal:  J Pharmacokinet Biopharm       Date:  1996-12

4.  Mathematical modeling of opiate binding to mouse brain membrane.

Authors:  H D Landahl; J Garzón; N M Lee
Journal:  Bull Math Biol       Date:  1985       Impact factor: 1.758

5.  Discrimination between neuropeptide Y and peptide YY in the rat tail artery by the neuropeptide Y1-selective antagonist, BIBP 3226.

Authors:  H Gicquiaux; M Tschöpl; H N Doods; B Bucher
Journal:  Br J Pharmacol       Date:  1996-12       Impact factor: 8.739

6.  Interaction of naloxone with the opioid receptor complex in vitro.

Authors:  R B Rothman; T C Westfall
Journal:  Neurochem Res       Date:  1982-11       Impact factor: 3.996

7.  Multiple opioid receptors: an examination of the dissociation of [3H]leucine enkephalin from rat brain membranes.

Authors:  R B Rothman; T C Westfall
Journal:  Neurochem Res       Date:  1983-02       Impact factor: 3.996

8.  Delta-opioid mediated inhibitions of acute and prolonged noxious-evoked responses in rat dorsal horn neurones.

Authors:  A F Sullivan; A H Dickenson; B P Roques
Journal:  Br J Pharmacol       Date:  1989-11       Impact factor: 8.739

9.  Highly selective photoaffinity labeling of mu and delta opioid receptors.

Authors:  C Garbay-Jaureguiberry; A Robichon; V Daugé; P Rossignol; B P Roques
Journal:  Proc Natl Acad Sci U S A       Date:  1984-12       Impact factor: 11.205

10.  Interaction between the mu-agonist dermorphin and the delta-agonist [D-Ala2, Glu4]deltorphin in supraspinal antinociception and delta-opioid receptor binding.

Authors:  L Negri; G Improta; R Lattanzi; R L Potenza; F Luchetti; P Melchiorri
Journal:  Br J Pharmacol       Date:  1995-12       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.